跳到正文
原文
Endpoints News 生物医药· Max Bayer·· 2026-10-15AI 评分17

FDA新框架向一致性而非灵活性倾斜

New FDA framework tilts toward consistency over flexibility

AI 导读

FDA新框架向一致性而非灵活性倾斜。FDA多位时任代理领导今夏表示,评估罕见病药物时,监管灵活性并非该机构追求的标准。

正文

Then-act­ing FDA lead­ers said over the sum­mer that reg­u­la­to­ry flex­i­bil­i­ty wasn’t the stan­dard they were striv­ing for when the agency gauges rare dis­ease drugs.

Now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news